Company intelligence / Profile preview
IAMA Therapeutics
Genoa, Italyiamatherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
IAMA Therapeutics has successfully dosed the first two cohorts of subjects and started dosing the third cohort in their Phase 1 study of IAMA-6 for the treatment of autism and epilepsy as of February 2024. The first subject was dosed in January 2024.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Evotec (multi-phase strategic provider agreement)The Sapienza University of Rome (sponsored research agreement)
Beyond the preview
Go deeper on IAMA Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IAMA Therapeutics.